DISCOVER THE BENEFITS OF TREATING OAB WITH GEMTESA9
URGENCY IMPROVEMENT • Proven urgency reduction data in its label9
• Statistically significant reduction of all 3 key OAB symptoms* vs placebo at 12 weeks — including urgency8,9‡
• No overall differences in safety or effectiveness of GEMTESA have been observed between patients 65 years of age and older and younger adult patients10
ONE CRUSHABLE DOSE
• Once-daily 75 mg dose with no titration, to be taken with or without food and swallowed whole with a glass of water9
• In adults, GEMTESA tablets may be crushed, mixed with a tablespoon (~15 mL) of applesauce, and taken immediately with a glass of water9
Not actual patient.
SAFETY & TOLERABILITY • No blood pressure warning in its label9 • No known association with cognitive decline for the β3
VISIT
GEMTESA.COM/HCP TO LEARN MORE ABOUT EFFICACY AND SAFETY FOR THE ELDERLY (65+)
‡
The efficacy of GEMTESA was evaluated in a pivotal 12-week, double-blind, randomized, placebo- and active-controlled trial in patients with OAB (UUI, urgency, and urinary frequency). For study entry, patients had to have symptoms of OAB for at least 3 months with an average of 8 or more micturitions per day and at least 1 UUI per day, or an average of 8 or more micturitions per day and an average of at least 3 urgency episodes per day. A total of 1515 patients received at least 1 daily dose of placebo (n=540), GEMTESA 75 mg (n=545), or an active-control treatment (n=430). The majority of patients were Caucasian (78%) and female (85%) with a mean age of 60 (range 18 to 93) years.3,9
IMPORTANT SAFETY INFORMATION (CONT’D) ADVERSE REACTIONS
Most common adverse reactions (≥2%) reported with GEMTESA were headache, urinary tract infection, nasopharyngitis, diarrhea, nausea, and upper respiratory tract infection.
Please see accompanying Brief Summary on the following pages.
References (cont'd): of overactive bladder. J Med Chem. 2016;59(2):609-623. doi:10.1021/
acs.jmedchem.5b01372 9. GEMTESA [prescribing information]. Irvine, CA: Urovant Sciences; 2020. 10. Varano S, Staskin D, Frankel J, Shortino D, Jankowich R, Mudd PN Jr. Efficacy and safety of once-daily vibegron for treatment of overactive bladder in patients aged ≥65 and ≥75 years: subpopulation analysis from the EMPOWUR randomized, international, phase III study. Drugs Aging. 2021;38(2):137-146. doi:10.1007/s40266-020-00829-z 11. Welk B, McArthur E. Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study. BJU Int. 2020;126(1):183-190. doi:10.1111/bju.15040
-agonist class11
UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES Logo, GEMTESA, and the GEMTESA Logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.
©2021 Urovant Sciences. US-VBGN-2100436 12/21
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60
